Oscar Health, Inc. (OSCR) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Oscar Health (OSCR) by buying shares or fractional shares at any major broker, or as one holding in a healthcare or thematic basket. The thesis is a bet on a technology-first health insurer that has finally turned profitable while growing membership faster than the industry, so the wager is that its digital model and licensable +Oscar platform let it out-execute legacy insurers. As of October 16, 2026 the stock closed at ~$32.68, up ~118% year to date, for a market cap near $10.1 billion. The single biggest risk is policy: Oscar is a near pure-play seller of Affordable Care Act marketplace plans, so the fate of enhanced federal premium subsidies drives enrollment, the risk pool, and earnings more than anything management does.
OSCR stock price
As of 2026-11-16, Oscar Health, Inc. (OSCR) last closed at $31.33, up 119.9% over the past year. Over the past 52 weeks it has traded between $10.85 and $35.19.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Oscar Health, Inc.'s investor relations page. Walnut is informational, not investment advice.
OSCR key stats
At $31.33 on November 16, 2026, Oscar Health, Inc. (OSCR) has a market cap of $9.7B and a P/E of 13.9 on trailing earnings (13.6 on forward earnings).
- Market cap
- $9.7B
- P/E (trailing)
- 13.9
- P/E (forward)
- 13.6
- EPS (trailing 12 months)
- $2.25
- Price to book
- 4.4
- Beta
- 2.49
Market cap, P/E and yield are measured at the $31.33 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Oscar Health, Inc. (OSCR)?
The last two weeks for Oscar Health, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- OSCR closed at $31.33 on November 16, 2026, down 2.5% over the past five trading days (from $32.14).
- On November 16, 2026, Oscar Health, Inc. filed an 8-K with the SEC reporting a change in its directors or officers (Item 5.02). Read the 8-K on sec.gov
- On November 5, 2026, Oscar Health, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 5, 2026, Oscar Health, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 6, 2026, Piper Sandler lowered its target to $45.00 from $48.00 (Overweight).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Oscar Health, Inc. (OSCR) do?
Oscar Health is a US health insurance company built around a digital-first member experience rather than the paperwork and call centers of legacy insurers. The vast majority of its money comes from premiums on individual and family health plans sold through the Affordable Care Act (ACA) public marketplaces, where by early 2026 it had grown to roughly 3.2 million members, up about 56% year over year, making it one of the larger players on the exchanges. Alongside the insurance business it runs +Oscar, a technology platform it licenses to other healthcare organizations, plus brokerage and enrollment tools; that platform revenue is small today but growing faster than premiums and carries higher margins. The company was founded in 2012 by Mario Schlosser, Kevin Nazemi, and Joshua Kushner, and is now led by chief executive Mark Bertolini, a former Aetna CEO.
The investment picture in 2026 is a profitability turnaround meeting a policy overhang. After losing ~$443 million in 2025, Oscar posted a record first quarter (revenue of ~$4.65 billion and net income near $679 million, EPS $2.07 vs a $1.10 estimate) and followed it with a strong second quarter: revenue of ~$4.88 billion, up ~70% year over year, and net income of ~$362 million, with EPS of $1.10 against a $0.38 consensus. Trailing revenue has reached ~$15.3 billion and trailing net income ~$551 million, and the company holds ~$8.6 billion of cash and investments against ~$0.5 billion of debt. The stock has risen ~118% year to date. But Oscar is essentially a pure-play ACA insurer, which makes it unusually sensitive to the enhanced premium tax credits that made marketplace coverage cheap for millions, and ACA results are seasonal: analysts expect a loss of ~$0.17 per share in the third quarter (reported November 5, 2026) and ~$1.08 in the fourth. The result is a stock that can move sharply on legislative headlines and on how quickly claims build through the year.
What's driving Oscar Health, Inc. (OSCR)?
1. Membership growth and share gains
Oscar grew to about 3.2 million members in early 2026, roughly 56% higher than a year earlier, expanding faster than the overall ACA marketplace. Revenue growth accelerated to ~70% year over year in the second quarter, and analysts expect ~$18.7 billion of revenue for full-year 2026 and ~$20.8 billion in 2027. The bet is that a simpler digital experience keeps winning enrollees from legacy carriers.
2. Turn to profitability
After years of losses, Oscar reached record profitability, reporting Q1 2026 net income near $679 million with a medical loss ratio of about 70.5%, down roughly 490 basis points year over year, and Q2 net income of ~$362 million. Both quarters beat EPS estimates by a wide margin. Consensus now sits at ~$1.94 of EPS for 2026 and ~$2.22 for 2027. Sustained profit through the seasonally heavier back half is the core of the re-rating story.
3. The +Oscar technology platform
Beyond selling insurance, Oscar licenses its +Oscar technology stack (claims automation, member engagement, care navigation) to other healthcare organizations. This platform revenue is still a small slice but grows faster than premiums and carries higher margins, giving Oscar a second, less capital-intensive line that is not purely a bet on the ACA marketplace.
4. Operating leverage and automation
Oscar leans on automation, citing very high claims auto-adjudication rates, to run leaner than traditional insurers. Its SG&A ratio improved toward roughly 15% as membership scaled, and trailing operating margin reached ~8%. If it can keep administrative costs falling as a share of revenue while enrollment grows, incremental premium dollars should convert to profit at a higher rate than for slower peers.
What are the risks to Oscar Health, Inc. (OSCR)?
The dominant risk is policy. Oscar is a near pure-play ACA marketplace insurer, so the status of enhanced federal premium tax credits is an existential-level variable: without them, marketplace premiums could more than double for many enrollees, healthier members may drop coverage, and the remaining risk pool would skew sicker and more expensive. Oscar itself took a weighted-average rate increase near 28% for 2026 partly to account for worsening morbidity, and October 2026 coverage of managed-care stocks has flagged election and healthcare-cost pressure. Results are also highly seasonal: 2025 swung from profit early in the year to losses of ~$137 million in Q3 and ~$353 million in Q4, and analysts again expect losses in Q3 and Q4 2026. On top of that, Oscar competes against far larger, better-capitalized insurers, and any spike in medical costs, adverse regulatory change, or execution stumble hits a company still proving it can stay profitable across a full year. After a ~118% rise in 2026, the stock trades near its 52-week high of ~$35, and the average analyst rating is hold.
What is the Oscar Health, Inc. (OSCR) forecast?
10 analysts publish price targets on OSCR, averaging $37.00 as of November 2026, or +18.1% against the $31.33 share price on November 16, 2026. The published targets run from $27.00 to $49.00, a moderate spread, and the ratings split 3 buy, 7 hold, 1 sell. Over the last six months there have been 10 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full OSCR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is OSCR a buy or a sell?
We give no verdict on Oscar Health, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Membership growth and share gains. Oscar grew to about 3.2 million members in early 2026, roughly 56% higher than a year earlier, expanding faster than the overall ACA marketplace. The most optimistic published target, $49.00, assumes this works close to its best case.
The case against. The dominant risk is policy. The most pessimistic target, $27.00, is roughly what OSCR is worth if this bites instead.
Read the full bull and bear case on OSCR, including what would have to change to break either one. Walnut is not an investment adviser.
Has Oscar Health, Inc. (OSCR) split its stock?
No. Oscar Health, Inc. (OSCR) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Oscar Health, Inc. (OSCR) valued?
Market cap, P/E and dividend yield at today's price are in the OSCR key stats above. The business figures below come from Oscar Health, Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$15.3 billion
- Revenue growth (Q2 2026, YoY): ~70% (Q2 revenue ~$4.88 billion)
- Net income (TTM): ~$551 million (EPS ~$1.29); Q2 2026 ~$362 million
- Margins: Operating ~8%, net ~3.6%
- Members: ~3.2 million as of early 2026, up ~56% year over year
As of October 2026: Figures are approximate and tied to the asOf date; verify live numbers before acting. OSCR has more than doubled in 2026, yet it still trades at about 0.66x trailing sales and ~15x forward earnings, low for a company growing revenue 70%, because the market prices in ACA-policy risk and expected second-half losses. Analysts' mean target of ~$36 sits only about 11% above the current price.
Which ETFs hold Oscar Health, Inc. (OSCR)?
If you want OSCR exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.
| ETF | Name | % in OSCR | Expense ratio | |
|---|---|---|---|---|
| FESM | Fidelity Enhanced Small Cap Core ETF | 0.8% | 0.28% |
Who competes with Oscar Health, Inc. (OSCR)?
Large diversified health insurers
National managed-care giants such as UnitedHealth Group, Elevance Health, Cigna, Humana, and CVS Health's Aetna dwarf Oscar in scale, capital, and provider relationships. They compete across employer, Medicare, and Medicaid lines that Oscar largely does not, and their size lets them absorb marketplace volatility that hits a focused player like Oscar harder.
ACA marketplace-focused insurers
Insurers with heavy individual-exchange exposure, most notably Centene (a leading ACA marketplace carrier) and Molina, along with regional Blue Cross plans like Florida Blue, compete directly for the same subsidized enrollees Oscar targets. This is where Oscar wins or loses members, and where subsidy policy changes hit every player at once.
Technology-driven and newer insurers
Digital-first and disruptor insurers such as Clover Health, plus Oscar's own +Oscar platform customers and health-tech firms like Collective Health, compete on member experience, automation, and data. This is the arena where Oscar's technology differentiation matters most, though several earlier challengers in the category have struggled or exited.
What stocks are similar to Oscar Health, Inc. (OSCR)?
Other names that sit close to OSCR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Oscar Health, Inc. (OSCR)
There are three common ways to get OSCR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FESM), which spreads the position across many companies. Or build it into a focused thematic portfolio, so OSCR sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where OSCR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Oscar Health, Inc. (OSCR)
Oscar Health is a technology-driven ACA marketplace insurer that posted two profitable quarters in a row in 2026 (net income of ~$679 million in Q1 and ~$362 million in Q2) on revenue up 50-70% year over year, and its stock has more than doubled this year. But earnings are seasonal, analysts expect losses in the second half, and results live and die by federal subsidy policy, so the story is as much about Washington as about the company.
More on Oscar Health, Inc. (OSCR)
Whether OSCR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is OSCR a buy or a sell?, and where the stock could go from here in the OSCR stock forecast.
For income investors, whether OSCR pays a dividend and how the payout looks is covered in does OSCR pay a dividend? And to weigh OSCR against a peer, read the full side-by-side comparisons: OSCR vs UNH and OSCR vs ELV.
Wondering how OSCR fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Oscar Health, Inc.
Ask Walnut's AI anything about OSCR and see how it fits what you own.
FAQ
Is OSCR a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice; Walnut is not an investment adviser. The bull case is a real turn to profitability, revenue growth of ~70%, two big earnings beats in 2026, and a technology platform that runs leaner than legacy insurers. The bear case is that Oscar is a near pure-play ACA insurer whose earnings hinge on federal subsidy policy, analysts expect second-half losses, and the stock has already risen ~118% this year. Weigh both against your own portfolio.
What does Oscar Health do?
+
Oscar Health is a US health insurance company that sells individual and family health plans, primarily through the Affordable Care Act marketplaces, with a digital-first member experience. Most of its revenue comes from insurance premiums. It also runs +Oscar, a technology platform it licenses to other healthcare organizations, plus brokerage and enrollment services.
Why did OSCR stock rise so much in 2026?
+
The stock is up ~118% year to date as of October 16, 2026 after Oscar reported a record first quarter (net income near $679 million) and a strong second quarter (net income ~$362 million on revenue up ~70%), both well ahead of estimates. Membership surged about 56% and the medical loss ratio improved. Optimism about ACA subsidy policy also lifted the shares on several occasions.
What is the biggest risk with Oscar Health?
+
Policy is the central risk. Oscar is a near pure-play ACA marketplace insurer, so it is unusually exposed to the enhanced federal premium tax credits. Without them, premiums could spike, healthier members may leave, and the remaining risk pool would worsen. That makes the stock sensitive to legislative and election headlines, on top of the seasonal swing to losses analysts expect in the second half of 2026.
Does Oscar Health pay a dividend?
+
Oscar Health does not pay a dividend. As a company that only recently turned profitable, it reinvests cash into growth, membership, and its technology platform rather than returning it to shareholders. Any return from OSCR would come from share-price movement rather than income, which matters if you are building a portfolio for current yield.
How does Oscar Health make money?
+
The large majority of Oscar's revenue is health insurance premiums paid by members for coverage, mostly through ACA marketplace plans. It keeps the difference between premiums collected and medical claims plus administrative costs, a gap tracked by the medical loss ratio. A smaller but faster-growing piece comes from licensing its +Oscar technology platform to other healthcare organizations.
Why are Oscar's quarterly results so volatile?
+
ACA insurance is seasonal. Claims tend to build through the year, so the medical loss ratio is usually lowest early and rises later, which is why Oscar can post a strong first-half profit and then losses in later quarters. In 2025 it lost ~$137 million in Q3 and ~$353 million in Q4, and for 2026 analysts expect losses of ~$0.17 per share in Q3 and ~$1.08 in Q4 even after a profitable first half. Enrollment timing and rate changes add to the swings.
Who runs Oscar Health and who founded it?
+
Oscar Health was founded in 2012 by Mario Schlosser, Kevin Nazemi, and Joshua Kushner. It is now led by chief executive Mark Bertolini, a former Aetna CEO who brings deep managed-care experience. The company is headquartered in New York, employs about 2,300 people, and trades on the NYSE under the ticker OSCR.
How did Oscar Health do in its latest quarter?
+
In the second quarter of 2026 Oscar reported revenue of ~$4.88 billion, up ~70% year over year, and net income of ~$362 million. EPS of $1.10 beat the $0.38 consensus by a wide margin, following a first-quarter beat ($2.07 vs $1.10). Third-quarter results are scheduled for November 5, 2026, with consensus calling for a loss of ~$0.17 per share on ~$4.72 billion of revenue.
How has OSCR stock performed in 2026?
+
As of October 16, 2026 OSCR closed at ~$32.68, up ~118% year to date and ~55% over one year, near the top of its 52-week range of ~$10.69 to ~$35.01. The rally followed back-to-back profitable quarters that beat estimates, which took the market cap to roughly $10.1 billion.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Oscar Health, Inc.'s investor relations page or your broker before making investment decisions.